• Product Description:

Irmukin (Osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic Epidermal Growth Factor Receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.

  • Product Features:

Product Name Irmukin
Generic Name Osimertinib INN 80 mg
Packaging Irmukin Tablet: Each commercial box contains 3×10’s tablets in Alu-Alu blister pack.
Prescribing Information IRMUKIN(PDF)